Oncolytics' Cleverly Cut Subgroup Data Unlikely To Save Reolysin In NSCLC

August appears to be month of bad news for clinical developments in non-small cell lung cancer (NSCLC). Following Bristol-Myers Squibb Co.'s shocking Phase III failure for Opdivo (nivolumab) in first-line NSCLC, Oncolytics Biotech Inc. has also reported disappointing data for its lung cancer drug Reolysin.

Men and women split on sides, separation crack. Concept 3D illustration.

Oncolytics Biotech reported less than impressive Phase II NSCLC data for its cancer drug Reolysin (pelareorep) this week – and despite the company's best attempt to find statistical significant data in subgroup analyses, analysts are not convinced.

The Canadian firm reported on Aug. 10 data split by gender from the Phase II IND211 study, which enrolled patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout

 

There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.

BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory

 

The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.

J&J Keeps Faith In Nipocalimab’s $5bn Sales Target Despite RA Trial Setback

 
• By 

Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.